Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1995 1
1998 2
2000 1
2001 4
2002 4
2003 7
2004 2
2005 3
2006 4
2007 12
2008 10
2009 6
2010 8
2011 9
2012 10
2013 12
2014 10
2015 6
2016 6
2017 10
2018 7
2019 8
2020 11
2021 8
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

148 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL. Armand P, et al. Among authors: gulbas z. J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609651 Free PMC article. Clinical Trial.
Pembrolizumab in relapsed or refractory Richter syndrome.
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, Svoboda J, Stathis A, Chatterjee A, Orlowski R, Marinello P, Christian B. Armand P, et al. Among authors: gulbas z. Br J Haematol. 2020 Jul;190(2):e117-e120. doi: 10.1111/bjh.16762. Epub 2020 Jun 16. Br J Haematol. 2020. PMID: 32544980 Free PMC article. Clinical Trial. No abstract available.
Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
Durak Aras B, Isik S, Uskudar Teke H, Aslan A, Yavasoglu F, Gulbas Z, Demirkan F, Ozen H, Cilingir O, Inci NS, Gunden G, Bulduk T, Erzurumluoglu Gokalp E, Kocagil S, Artan S, Akay OM. Durak Aras B, et al. Among authors: gulbas z. Mol Cytogenet. 2021 Jan 6;14(1):2. doi: 10.1186/s13039-020-00522-1. Mol Cytogenet. 2021. PMID: 33407772 Free PMC article.
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Bekoz H, Ozbalak M, Karadurmus N, Paydas S, Turker A, Toptas T, Tuglular TF, Altuntas F, Cakar MK, Sonmez M, Gulbas Z, Demir N, Kaynar L, Yildirim R, Karadogan I, Arat M, Kapucu I, Aslan NA, Ozkocaman V, Turgut M, Yuksel MK, Ozcan M, Hacioglu SK, Barista I, Demirkaya M, Saydam G, Toprak SK, Yilmaz M, Demirkol O, Ferhanoglu B. Bekoz H, et al. Among authors: gulbas z. Ann Hematol. 2020 Nov;99(11):2565-2576. doi: 10.1007/s00277-020-04077-4. Epub 2020 Jun 7. Ann Hematol. 2020. PMID: 32507911 Clinical Trial.
Development of Small Molecule MEIS Inhibitors that modulate HSC activity.
Turan RD, Albayrak E, Uslu M, Siyah P, Alyazici LY, Kalkan BM, Aslan GS, Yucel D, Aksoz M, Tuysuz EC, Meric N, Durdagi S, Gulbas Z, Kocabas F. Turan RD, et al. Among authors: gulbas z. Sci Rep. 2020 May 14;10(1):7994. doi: 10.1038/s41598-020-64888-3. Sci Rep. 2020. PMID: 32409701 Free PMC article.
Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia.
Dholaria B, Labopin M, Angelucci E, Tischer J, Arat M, Ciceri F, Gülbas Z, Ozdogu H, Sica S, Diez-Martin JL, Koc Y, Pavlu J, Socié G, Giebel S, Savani BN, Nagler A, Mohty M. Dholaria B, et al. Among authors: gulbas z. Transplant Cell Ther. 2021 Feb;27(2):171.e1-171.e8. doi: 10.1016/j.jtct.2020.10.008. Epub 2020 Dec 11. Transplant Cell Ther. 2021. PMID: 33830029
148 results